Clinical manifestations of neuromyelitis optica in male and female patients

Neurological Research

Volumn 37, Issue 11, 2015, Pages 967-973

  Yin, Jianrui ^a   Long, Youming ^a   Shan, Fulan ^a   Fan, Yongxiang ^a   Wu, Linzhan ^a   Zhong, Rong ^a   Gao, Cong ^a   Chen, Xiaohui ^a   Gao, Qingchun ^a   Yang, Ning ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Aquaporin 4; Female antibody; Gender; Male; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4; ANTIBODY; AQP4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HAND PARESTHESIA; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; SPINAL CORD LESION; BRAIN; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SPINAL CORD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; AQUAPORIN 4; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; SPINAL CORD; YOUNG ADULT;

EID: 84942105112     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132815Y.0000000081     Document Type: Article

References (22)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9.
2. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003;9(5):521-5.
3. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80.
4. Tintore M, Arrambide G. Early onset multiple sclerosis: the role of gender. J Neurol Sci. 2009;286(1-2):31-4.
5. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286(1-2):18-23.
6. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14.
7. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
8. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibodypositive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;136(Pt 6):1834-49.
9. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-81.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52.
11. Granieri L, Marnetto F, Valentino P, Frau J, Patanella AK, Nytrova P, et al. Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. Plos One. 2012;7(6):e38896.
12. Lin A, Zhu J, Yao X, Lin S, Murong S, Li Z. Clinical manifestations and spinal cord magnetic resonance imaging findings in Chinese neuromyelitis optica patients. Eur Neurol. 2014;71(1-2):35-41.
13. Yang CS, Zhang DQ, Wang JH, Jin WN, Li MS, Liu J, et al. Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China. CNS Neurosci Ther. 2014; 20(1):32-9.
14. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81(14):1197-204.
15. LennonVA, WingerchukDM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.
16. Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74(9):736-42.
17. Simon K, Schmidt H, Loud S, Ascherio A. Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis. Mult Scler. 2015;21(6):703-9.
18. Collongues N, Marignier R, Jacob A, Leite M, Siva A, Paul F, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2013;20(8):1086-94.
19. Brum DG, Luizon MR, Santos AC, Lana-Peixoto MA, Rocha CF, Brito ML, et al. European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil. Plos ONE. 2013;8(3):e58925.
20. Papais-AlvarengaRM, Vasconcelos CC, Alves-Leon SV, BatistaE, Santos CM, Camargo SM, et al. The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.Mult Scler. 2014;20(3):374-81.
21. Cabre P, González-Quevedo A, Bonnan M, Saiz A, Olindo S, Graus F, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry. 2009;80(10):1162-4.
22. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21(7):866-74.